https://www.biopharmawatch.com/news/NRXP/nrxp-fda-update-preservative-free-ketamine BiopharmaWatch en 2026-09-15T19:11:00.000Z NRx Pharmaceuticals (Nasdaq: NRXP) Reports Update from the FDA Revising Previous Major Amendment to a Minor Amendment for Preservative-free Ketamine https://www.biopharmawatch.com/news/PRCT/lawsuit-notice-procept-biorobotics-investors BiopharmaWatch en 2026-09-15T17:15:00.000Z LAWSUIT NOTICE: NASDAQ: PRCT Investors who lost money with PROCEPT BioRobotics Corporation shares should contact the Shareholders Foundation https://www.biopharmawatch.com/news/FEED/envue-medical-nasdaq-listing-update BiopharmaWatch en 2026-09-15T16:45:00.000Z ENvue Medical Provides Nasdaq Listing Update https://www.biopharmawatch.com/news/GILD/gilead-paho-partnership-lenacapavir-hiv-prevention BiopharmaWatch en 2026-09-15T15:10:00.000Z Gilead and PAHO Announce Milestone Partnership to Accelerate Access to Twice-Yearly Lenacapavir for HIV Prevention Across Latin America and the Caribbean https://www.biopharmawatch.com/news/MEDP/supporting-complex-phase-i-studies-integrated-imaging BiopharmaWatch en 2026-09-15T14:15:39.000Z Supporting Complex Phase I Studies Through Integrated Imaging and Specialized Assessments https://www.biopharmawatch.com/news/NTHI/neonc-technologies-investor-focus-nthi BiopharmaWatch en 2026-09-15T13:53:00.000Z Investor Determination to Beat Cancer Puts NeOnc’s Novel Therapies and Patented Platform in Focus https://www.biopharmawatch.com/blog/biotech-catalysts-to-watch-week-of-2026-09-14 BiopharmaWatch en 2026-09-15T13:43:25.882Z Biotech Catalysts to Watch: Key Events and Insights for Investors https://www.biopharmawatch.com/news/HSTM/healthstream-private-placement-40-million BiopharmaWatch en 2026-09-15T13:25:00.000Z HealthStream Completes $40 Million Private Placement of Its Common Stock https://www.biopharmawatch.com/news/HSCS/heartsciences-fiscal-q1-2027-results-business-update BiopharmaWatch en 2026-09-15T13:25:00.000Z HeartSciences Reports Fiscal First Quarter 2027 Financial Results and Provides Business Update https://www.biopharmawatch.com/news/GTBP/gt-biopharma-gtb-5550-multiple-myeloma-indication BiopharmaWatch en 2026-09-15T13:15:00.000Z GT Biopharma Announces Potential New Indication for GTB-5550, a B7-H3-Targeted Natural Killer (NK) Cell Engager, for Multiple Myeloma https://www.biopharmawatch.com/news/BTMD/solfarcos-expands-us-market-partnerships BiopharmaWatch en 2026-09-15T13:00:00.000Z Biotech Innovator Solfarcos Brings Capabilities Behind K18 Development to New Markets https://www.biopharmawatch.com/news/LFMD/att-free-access-virtual-healthcare-lifemd BiopharmaWatch en 2026-09-15T13:00:00.000Z AT&T Becomes the First and Only Carrier to Offer Free Access to Virtual Healthcare Powered by LifeMD https://www.biopharmawatch.com/news/FEMY/femasys-ob-gyn-expansion-femaseed-minnesota BiopharmaWatch en 2026-09-15T13:00:00.000Z Femasys Advances OB/GYN Expansion with Adoption of FemaSeed® Fertility Portfolio by Minnesota Women’s Care https://www.biopharmawatch.com/news/CLNN/clene-announces-4-million-registered-direct-offering BiopharmaWatch en 2026-09-15T13:00:00.000Z Clene Announces $4 Million Registered Direct Offering https://www.biopharmawatch.com/news/ERNA/ernexa-therapeutics-positive-preclinical-data-erna-201 BiopharmaWatch en 2026-09-15T12:42:00.000Z Ernexa Therapeutics Reports Positive Disease Modifying ERNA-201 Preclinical Data, Reinforcing iMSC Platform as Company Accelerates Oncology Strategy and ERNA-101 Toward First-in-Human Dosing https://www.biopharmawatch.com/news/CVM/cel-sci-keynote-multikine-6th-world-congress BiopharmaWatch en 2026-09-15T12:37:00.000Z CEL-SCI Invited to Deliver Keynote Address on Multikine at 6th World Congress on Otology, Rhinology and Laryngology https://www.biopharmawatch.com/news/HCA/hca-healthcare-acquisition-college-health-care-professions BiopharmaWatch en 2026-09-15T12:30:00.000Z HCA Healthcare Completes Acquisition of the College of Health Care Professions https://www.biopharmawatch.com/news/ABBV/abbvie-birdies-for-brain-health-pga-tour BiopharmaWatch en 2026-09-15T12:30:00.000Z AbbVie Named Official Pharmaceutical Sponsor of the PGA TOUR and 2026 Presidents Cup, Launches Birdies for Brain Health Campaign https://www.biopharmawatch.com/news/OBIO/orchestra-biomed-milestone-payment-vivasure-haemonetics BiopharmaWatch en 2026-09-15T12:30:00.000Z Orchestra BioMed Receives $6.1 Million Milestone Payment from Acquisition of Vivasure by Haemonetics https://www.biopharmawatch.com/news/PYPD/polypid-participation-fall-investor-conferences BiopharmaWatch en 2026-09-15T12:30:00.000Z PolyPid Announces Participation in Upcoming Fall Investor Conferences https://www.biopharmawatch.com/news/HYPR/hyperfine-completes-enrollment-contrast-pmr-study BiopharmaWatch en 2026-09-15T12:15:00.000Z Hyperfine Announces Completion of Enrollment in the Contrast PMR Study to Support the Submission to Expand Indications for Use of the Swoop® System with Contrast Agents https://www.biopharmawatch.com/news/MAIA/maia-biotechnology-stock-purchases-ceo-board-member BiopharmaWatch en 2026-09-15T12:15:00.000Z MAIA Biotechnology Announces Open Market Purchases of Company Stock by Long-Standing Board Member and CEO https://www.biopharmawatch.com/news/TMO/mayo-clinic-thermo-fisher-precure-launch BiopharmaWatch en 2026-09-15T12:00:00.000Z Mayo Clinic and Thermo Fisher Scientific launch Precure, LLC to identify signs of disease before symptoms appear https://www.biopharmawatch.com/news/ARDT/ardent-health-hospitals-us-news-best-hospitals-2026-2027 BiopharmaWatch en 2026-09-15T12:00:00.000Z Ardent Health Hospitals Earn Recognition in U.S. News & World Report’s 2026-2027 Best Hospitals Rankings https://www.biopharmawatch.com/news/GEHC/ge-healthcare-careintellect-operations-launch BiopharmaWatch en 2026-09-15T12:00:00.000Z GE HealthCare Announces CareIntellect for Operations, Helping Health Systems Optimize Resources and Expand Access to Care https://www.biopharmawatch.com/news/ENVB/enveric-biosciences-us-patent-allowance-mescaline-derivatives BiopharmaWatch en 2026-09-15T12:00:00.000Z Enveric Biosciences Secures New U.S. Patent Allowance for Next-Generation, Non-Hallucinogenic Mescaline Derivatives in EVM401 Series https://www.biopharmawatch.com/news/COYA/coya-therapeutics-phase-2-3-alstars-trial-100th-participant BiopharmaWatch en 2026-09-15T12:00:00.000Z Coya Therapeutics Announces Enrollment of 100th Participant in Phase 2/3 ALSTARS Trial of COYA 302 for the Treatment of ALS https://www.biopharmawatch.com/news/NUVB/nuvation-bio-ibtrozi-efficacy-ros1-nsclc-wclc-2026 BiopharmaWatch en 2026-09-15T12:00:00.000Z Nuvation Bio Announces New Analyses Reinforcing the Durable, Consistent Efficacy of IBTROZI® (taletrectinib) Across Key Patient Subgroups in Advanced ROS1+ NSCLC at 2026 World Conference on Lung Cancer https://www.biopharmawatch.com/news/BDMD/baird-medical-hc-wainwright-conference-2026 BiopharmaWatch en 2026-09-15T12:00:00.000Z Baird Medical to Present at the H.C. Wainwright 28th Annual Global Investment Conference https://www.biopharmawatch.com/news/LBRX/lb-pharmaceuticals-appoints-susan-kozauer-cmo BiopharmaWatch en 2026-09-15T12:00:00.000Z LB Pharmaceuticals Appoints Susan G. Kozauer, M.D. as Chief Medical Officer https://www.biopharmawatch.com/news/ALLR/allarity-therapeutics-japanese-patent-stenoparib-diagnostic BiopharmaWatch en 2026-09-15T12:00:00.000Z Allarity Therapeutics Granted Japanese Patent for Stenoparib DRP® Companion Diagnostic, Further Strengthening Stenoparib Development https://www.biopharmawatch.com/news/LEGN/legend-biotech-appoints-ingrid-zhang-ceo BiopharmaWatch en 2026-09-15T12:00:00.000Z Legend Biotech Appoints Ingrid Zhang as Chief Executive Officer https://www.biopharmawatch.com/news/MDT/sonus-medtronic-ai-maternal-health-monitoring BiopharmaWatch en 2026-09-15T12:00:00.000Z Sonus Microsystems and Medtronic Partner to Advance AI-Powered Maternal Health Monitoring https://www.biopharmawatch.com/news/COGT/cogent-biosciences-fda-acceptance-bezuclastinib-advsm BiopharmaWatch en 2026-09-15T12:00:00.000Z Cogent Biosciences Announces FDA Acceptance of New Drug Application (NDA) for Bezuclastinib in Patients with Advanced Systemic Mastocytosis (AdvSM) https://www.biopharmawatch.com/news/LFWD/lifeward-rewalk-exoskeleton-study-improvements BiopharmaWatch en 2026-09-15T12:00:00.000Z Peer-Reviewed Study of Lifeward’s ReWalk® Exoskeleton Reports Significant Improvements in Daily Activity Performance, Satisfaction, and Pain https://www.biopharmawatch.com/news/SCYX/scynexis-appoints-todd-minga-svp-research-development BiopharmaWatch en 2026-09-15T12:00:00.000Z SCYNEXIS Appoints Todd Minga, M.D., as Senior Vice President, Research & Development https://www.biopharmawatch.com/news/OSTX/os-therapies-uk-mhra-eu-ema-cmaa-filing BiopharmaWatch en 2026-09-15T11:46:00.000Z OS Therapies Announces Full Alignment with UK MHRA and EU EMA for Conditional Marketing Authorisation Application Filing https://www.biopharmawatch.com/news/EBS/emergent-ribbon-cutting-canton-manufacturing-facility BiopharmaWatch en 2026-09-15T11:45:00.000Z Media Advisory: Emergent to Host Ribbon Cutting Ceremony at Canton Manufacturing Facility https://www.biopharmawatch.com/news/VRTX/vertex-lindsey-vonn-journavx-awareness BiopharmaWatch en 2026-09-15T11:30:00.000Z Vertex Partners With World Champion Skier Lindsey Vonn to Raise Awareness of JOURNAVX®, a Non-Opioid Medicine Approved for the Treatment of Moderate-to-Severe Acute Pain https://www.biopharmawatch.com/news/ARWR/arrowhead-pharmaceuticals-aro-dimer-pa-clinical-data BiopharmaWatch en 2026-09-15T11:30:00.000Z Arrowhead Pharmaceuticals Announces Interim Topline Clinical Data for the First Dual-Functional RNAi Therapeutic for the Treatment of Mixed Hyperlipidemia https://www.biopharmawatch.com/news/BIVI/biovie-address-lc-trial-bezisterim-long-covid-results BiopharmaWatch en 2026-09-15T11:30:00.000Z BioVie Announces Topline Results from Phase 2 ADDRESS‑LC Trial Evaluating Bezisterim for the Treatment of Neurological Symptoms Associated with Long COVID https://www.biopharmawatch.com/news/PLSE/pulse-biosciences-preciise-btn-clinical-study-enrollment BiopharmaWatch en 2026-09-15T11:00:00.000Z Pulse Biosciences Completes Enrollment in the PRECISE-BTN Clinical Study Evaluating the nPulse™ Vybrance™ Percutaneous Electrode System for Symptomatic Benign Thyroid Nodules https://www.biopharmawatch.com/news/RCKT/rocket-pharmaceuticals-fda-alignment-rp-a501-danon-disease BiopharmaWatch en 2026-09-15T11:00:00.000Z Rocket Pharmaceuticals Announces FDA Alignment on Path to Complete Pivotal Phase 2 Trial of RP-A501 in Danon Disease https://www.biopharmawatch.com/news/OCUL/ocular-therapeutix-pre-nda-meeting-axpaxli-wet-amd BiopharmaWatch en 2026-09-15T11:00:00.000Z Ocular Therapeutix™ Announces Positive Pre-NDA Meeting with U.S. FDA for AXPAXLI™ in Wet AMD https://www.biopharmawatch.com/news/CNTB/connect-biopharma-positive-data-rademikibart-asthma BiopharmaWatch en 2026-09-15T11:00:00.000Z Connect Biopharma Announces Positive Preliminary Topline Data from its Global Phase 2 Study of Rademikibart as an Add-on Treatment for Acute Exacerbations in Adult and Adolescent Participants with Asthma and Type 2 Inflammation https://www.biopharmawatch.com/news/MSLE/satellos-present-world-muscle-society-congress BiopharmaWatch en 2026-09-15T11:00:00.000Z Satellos to Present at the 31st Annual Congress of the World Muscle Society https://www.biopharmawatch.com/news/BLSM/blossomhill-therapeutics-bh-30643-phase-1-2-trial-results BiopharmaWatch en 2026-09-15T11:00:00.000Z BlossomHill Therapeutics Presents Updated Data from Ongoing Phase 1/2 SOLARA Trial Demonstrating Encouraging Anti-Tumor Activity of OMNI-EGFR™ Inhibitor BH-30643 in EGFR C797S-Positive NSCLC at IASLC 2026 World Conference on Lung Cancer https://www.biopharmawatch.com/news/CMPS/compass-pathways-change-tune-trd-launch BiopharmaWatch en 2026-09-15T10:30:00.000Z Compass Pathways Launches ‘Change the Tune in TRD’ in the U.S. to Advance HCP Understanding of Treatment-Resistant Depression at Psych Congress 2026 https://www.biopharmawatch.com/news/VERA/veras-trutakna-origins-3-trial-results BiopharmaWatch en 2026-09-15T10:30:00.000Z Vera Therapeutics Announces TRUTAKNA™ (atacicept-vymj) Stabilized eGFR and Prevented Kidney Disease Progression Through Two Years in ORIGIN 3 Final Efficacy Analysis in IgA Nephropathy https://www.biopharmawatch.com/news/SMMT/harmoni-data-wclc-2026-ivonescimab BiopharmaWatch en 2026-09-15T10:00:00.000Z Updated HARMONi Data Presented at WCLC 2026 Demonstrate Consistent Overall Survival Results with Ivonescimab Plus Chemotherapy in Western and Asian Patients https://www.biopharmawatch.com/news/PFSA/profusa-nasdaq-compliance-determination BiopharmaWatch en 2026-09-15T10:00:00.000Z Profusa, Inc. Receives Nasdaq Compliance Determination https://www.biopharmawatch.com/news/IBO/impact-biomedical-reverse-stock-split-merger-zoar BiopharmaWatch en 2026-09-15T01:26:00.000Z CORRECTED — Impact Biomedical Inc (NYSE: IBO) Announces 1 for 12.62 Reverse Stock Split to Pursue Completion of Merger with Zoar Limited (f/k/a Dr Ashleys Limited) https://www.biopharmawatch.com/news/LOBE/lobe-sciences-present-low-dose-l130-clinical-data BiopharmaWatch en 2026-09-14T23:00:00.000Z Lobe Sciences to Present Low-Dose L-130 Clinical Data at 9th Neuropsychiatric Drug Development Summit https://www.biopharmawatch.com/news/HCAT/health-catalyst-inducement-awards-nasdaq-rule-5635 BiopharmaWatch en 2026-09-14T22:32:00.000Z Health Catalyst Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) https://www.biopharmawatch.com/news/ARMP/lead-clinical-research-associate-armata-pharmaceuticals BiopharmaWatch en 2026-09-14T22:31:00.000Z Lead Clinical Research Associate (Lead CRA) https://www.biopharmawatch.com/news/ASND/ascendis-regains-transcon-rights-metabolic-cardiovascular BiopharmaWatch en 2026-09-14T22:00:00.000Z Ascendis to Regain Rights to TransCon® Technology in Metabolic and Cardiovascular Diseases https://www.biopharmawatch.com/news/ASND/ascendis-share-repurchase-program-400-million BiopharmaWatch en 2026-09-14T22:00:00.000Z Ascendis Announces Planned $400 Million Share Repurchase Program https://www.biopharmawatch.com/news/HYFT/mindwalk-reports-revenue-growth-fiscal-q1-2027 BiopharmaWatch en 2026-09-14T20:56:00.000Z MindWalk Reports 21% Revenue Growth and Gross Margin Expansion to 59% in Fiscal First Quarter 2027 https://www.biopharmawatch.com/news/DXCM/dexcom-promotes-jereme-sylvain-coo BiopharmaWatch en 2026-09-14T20:30:00.000Z Dexcom Promotes Jereme Sylvain to Chief Operating Officer https://www.biopharmawatch.com/news/HCAT/health-catalyst-board-appointment-tami-reller BiopharmaWatch en 2026-09-14T20:19:00.000Z Health Catalyst Strengthens Its Board with the Appointment of Tami Reller https://www.biopharmawatch.com/news/AGMB/agomab-announces-positive-phase-1-results-agmb-447-patients-idiopathic BiopharmaWatch en 2026-09-14T20:05:30.000Z Agomab Announces Positive Phase 1 Results for AGMB-447 in Patients with Idiopathic Pulmonary Fibrosis and Design of Phase 2 INSPIRIA Study https://www.biopharmawatch.com/news/GH/guardant-health-shield-blood-test-evicore-coverage BiopharmaWatch en 2026-09-14T20:05:00.000Z Guardant Health’s Shield Blood Test Covered by EviCore by Evernorth for Colorectal Cancer Screening https://www.biopharmawatch.com/news/CTNM/contineum-therapeutics-phase-2-results-depression-treatment BiopharmaWatch en 2026-09-14T20:05:00.000Z Contineum Therapeutics Reports Phase 2 Results for JNJ-5120/PIPE-307 for the Treatment of Major Depressive Disorder https://www.biopharmawatch.com/news/YARW/yarrow-bioscience-closes-172-5-million-offering BiopharmaWatch en 2026-09-14T20:05:00.000Z Yarrow Bioscience Announces Closing of its $172.5 Million Underwritten Public Offering Including Full Exercise of the Underwriters’ Option to Purchase Additional Shares https://www.biopharmawatch.com/news/RVMD/revolution-medicines-fda-breakthrough-therapy-rasonque BiopharmaWatch en 2026-09-14T20:05:00.000Z Revolution Medicines Announces U.S. FDA Breakthrough Therapy Designation for RASONQUE™ (daraxonrasib) in Combination with Chemotherapy for First Line Metastatic Pancreatic Cancer https://www.biopharmawatch.com/news/PETS/petmeds-appoints-andrew-parry-as-cto BiopharmaWatch en 2026-09-14T20:05:00.000Z PetMeds Appoints Andrew Parry as Chief Technology Officer https://www.biopharmawatch.com/news/BIVI/biovie-conference-call-address-lc-trial-bezisterim BiopharmaWatch en 2026-09-14T20:01:00.000Z BioVie to Host Conference Call to Discuss Topline Data from Phase 2 ADDRESS-LC Trial and the Potential of Bezisterim in Long Covid https://www.biopharmawatch.com/news/BDSX/biodesix-brianna-phillips-raps-socra-meetings BiopharmaWatch en 2026-09-14T20:01:00.000Z Biodesix Quality and Regulatory Executive, Brianna Phillips, to speak at upcoming RAPS and SOCRA Annual Meetings https://www.biopharmawatch.com/news/KMTS/kestra-medical-q1-fiscal-2027-results BiopharmaWatch en 2026-09-14T20:01:00.000Z Kestra Medical Technologies Reports First Quarter Fiscal 2027 Financial Results https://www.biopharmawatch.com/news/SION/sionna-therapeutics-sion-451-sion-2222-phase-2a-trial BiopharmaWatch en 2026-09-14T20:01:00.000Z Sionna Therapeutics Announces Plans to Advance SION-451 + SION-2222 Dual Combination into Phase 2a Proof-of-Concept Trial https://www.biopharmawatch.com/news/BNTC/benitec-biopharma-full-year-2026-financial-results BiopharmaWatch en 2026-09-14T20:00:00.000Z Benitec Biopharma Releases Full Year 2026 Financial Results and Provides Operational Update https://www.biopharmawatch.com/news/ACB/aurora-cannabis-refutes-curaleaf-bid BiopharmaWatch en 2026-09-14T18:12:00.000Z Aurora Cannabis Refutes Curaleaf's Latest Attempt To Distract Shareholders From The Facts https://www.biopharmawatch.com/news/HCA/meditech-expanse-ehr-hca-healthcare-implementation BiopharmaWatch en 2026-09-14T17:30:00.000Z MEDITECH Expanse EHR Live Across First Full U.S. Divisions of HCA Healthcare https://www.biopharmawatch.com/news/TBLA/taboola-class-action-lawsuit-deadline-october-2026 BiopharmaWatch en 2026-09-14T16:47:00.000Z NASDAQ: TBLA INVESTOR ALERT: Berger Montague Advises Taboola.com Ltd. (NASDAQ: TBLA) Investors of an October 20, 2026 Deadline https://www.biopharmawatch.com/news/BBNX/beta-bionics-securities-class-action-illet-fda-compliance BiopharmaWatch en 2026-09-14T16:46:00.000Z Beta Bionics (NASDAQ: BBNX) Faces Securities Class Action Amid iLet FDA Compliance -- HBSS https://www.biopharmawatch.com/news/COSM/cosmos-health-tokenize-ccx0722-ip-innovative-structure BiopharmaWatch en 2026-09-14T15:59:00.000Z Cosmos Health Moves to Tokenize CCX0722 Intellectual Property in Innovative Non-Dilutive Structure, Eyes $562 Billion Weight-Management Market https://www.biopharmawatch.com/news/BFRI/biofrontera-fda-approval-ameluz-sbcc-treatment BiopharmaWatch en 2026-09-14T13:26:00.000Z Biofrontera Announces FDA Approval of Ameluz® Red Light PDT for the Treatment of Superficial Basal Cell Carcinoma https://www.biopharmawatch.com/news/HSTM/healthstream-defines-enterprise-clinical-workforce-platform BiopharmaWatch en 2026-09-14T13:25:00.000Z HealthStream Defines a New Enterprise Category Alongside the EHR and ERP, the Enterprise Clinical Workforce Platform (ECWP) https://www.biopharmawatch.com/news/PACS/pacs-group-presentation-jefferies-conference-2026 BiopharmaWatch en 2026-09-14T13:15:00.000Z PACS Group, Inc. to Present at the 2026 Jefferies Healthcare Services and Technology Conference on September 15, 2026 https://www.biopharmawatch.com/news/NTHI/neonc-moves-neo100-regulatory-test BiopharmaWatch en 2026-09-14T13:07:00.000Z Insiders Continue Buying, as NeOnc Moves NEO100 Toward Its Next Regulatory Test https://www.biopharmawatch.com/news/ERNA/ernexa-therapeutics-hc-wainwright-conference-2026 BiopharmaWatch en 2026-09-14T13:05:00.000Z Ernexa Therapeutics to Present at the H.C. Wainwright 28th Annual Global Investment Conference https://www.biopharmawatch.com/news/BMRN/biomarin-appoints-robert-plenge-board-directors BiopharmaWatch en 2026-09-14T13:05:00.000Z BioMarin Announces Appointment of Robert Plenge, M.D., Ph.D., Chief Research Officer of Bristol Myers Squibb, to Board of Directors https://www.biopharmawatch.com/news/SNY/sanofi-cheplapharm-strategic-partnership-mature-medicines BiopharmaWatch en 2026-09-14T13:03:00.000Z Press Release: Sanofi and Cheplapharm to create new strategic partnership in mature medicines https://www.biopharmawatch.com/news/AZN/susan-g-komen-astrazeneca-patient-navigation BiopharmaWatch en 2026-09-14T13:00:00.000Z Susan G. Komen® and AstraZeneca Partnership to Make Patient Navigation Available to All https://www.biopharmawatch.com/news/CON/concentra-expands-florida-footprint-daytona-beach BiopharmaWatch en 2026-09-14T13:00:00.000Z Concentra Expands Florida Footprint with New Daytona Beach Medical Center https://www.biopharmawatch.com/news/AMGN/fda-approves-reduced-monitoring-time-imdelltra BiopharmaWatch en 2026-09-14T13:00:00.000Z FDA APPROVES REDUCED MONITORING TIME FOR FIRST TWO DOSES OF IMDELLTRA® https://www.biopharmawatch.com/news/DARE/dare-bioscience-sildenafil-cream-phase-1-study BiopharmaWatch en 2026-09-14T12:50:00.000Z Daré Bioscience Announces Peer-Reviewed Publication of Phase 1 Sildenafil Cream Study in Men Demonstrating Substantially Lower Systemic Exposure Versus Oral Sildenafil https://www.biopharmawatch.com/news/HYFT/mindwalk-secures-30-million-credit-facility BiopharmaWatch en 2026-09-14T12:46:00.000Z MindWalk Lands Binding Commitment for US$30 Million Unsecured Credit Facility to Fund Biologics Programs and Commercial Expansion https://www.biopharmawatch.com/news/DWTX/dogwood-completes-enrollment-halneuron-phase-2b-trial BiopharmaWatch en 2026-09-14T12:45:00.000Z Dogwood Announces Completion of Enrollment in Ongoing Halneuron® Phase 2b Trial https://www.biopharmawatch.com/news/AVXL/iss-recommends-anavex-director-nominees BiopharmaWatch en 2026-09-14T12:38:12.000Z Leading Independent Proxy Advisory Firm ISS Recommends Stockholders Vote “FOR” All Six of Anavex’s Highly Qualified Director Nominees https://www.biopharmawatch.com/news/MBRX/moleculin-annamycin-data-aacr-conference BiopharmaWatch en 2026-09-14T12:35:12.000Z Moleculin to Showcase New Annamycin Data at AACR Conference on Pancreatic Cancer and Two European Scientific Meetings https://www.biopharmawatch.com/news/CRDF/cardiff-oncology-nerviano-license-agreement-amendment BiopharmaWatch en 2026-09-14T12:30:00.000Z Cardiff Oncology and Nerviano Medical Sciences Amend their 2017 Exclusive License Agreement https://www.biopharmawatch.com/news/ONCO/onconetix-bridge-financing-realbotix-acquisition BiopharmaWatch en 2026-09-14T12:30:00.000Z Onconetix Provides Strategic Bridge Financing to Realbotix LLC in Support of Pending Acquisition https://www.biopharmawatch.com/news/TNYA/tenaya-therapeutics-fda-rmat-designation-tn-401 BiopharmaWatch en 2026-09-14T12:30:00.000Z Tenaya Therapeutics Granted U.S. FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for TN-401 for the Treatment of PKP2-Associated Arrhythmogenic Right Ventricular Cardiomyopathy https://www.biopharmawatch.com/news/VNRX/volitionrx-prepayment-senior-secured-note BiopharmaWatch en 2026-09-14T12:17:00.000Z VolitionRx Limited Announces Pre-Payment in Full of $7.5 million Senior Secured Convertible Promissory Note Due May 20, 2027 https://www.biopharmawatch.com/news/PBM/psyence-texas-ibogaine-research-corporation BiopharmaWatch en 2026-09-14T12:01:32.000Z Psyence BioMed Establishes Texas Ibogaine Research Corporation to Advance U.S. Ibogaine Development https://www.biopharmawatch.com/news/TELO/telomir-research-ohio-state-anti-cancer-activity BiopharmaWatch en 2026-09-14T12:00:00.000Z Telomir Announces Research with The Ohio State University Demonstrating In-Vitro Anti-Cancer Activity in Human and Canine Osteosarcoma Models https://www.biopharmawatch.com/news/QTRX/quanterix-names-dr-yuri-fesko-cmo BiopharmaWatch en 2026-09-14T12:00:00.000Z Quanterix Names Dr. Yuri Fesko Chief Medical Officer https://www.biopharmawatch.com/news/ADUS/addus-homecare-acquires-accentcare-personal-care-division BiopharmaWatch en 2026-09-14T12:00:00.000Z Addus HomeCare Announces a Definitive Agreement to Acquire Personal Care Division of AccentCare https://www.biopharmawatch.com/news/OABI/omniab-investor-analyst-day-october-2026 BiopharmaWatch en 2026-09-14T12:00:00.000Z OmniAb to Host Investor & Analyst Day on October 6, 2026 https://www.biopharmawatch.com/news/JANX/janux-therapeutics-phase-1-study-janx013 BiopharmaWatch en 2026-09-14T12:00:00.000Z Janux Therapeutics Announces First Patient Dosed in Phase 1 Study of JANX013 https://www.biopharmawatch.com/news/WAT/waters-launches-bd-facsdiscover-a7-cell-analyzer BiopharmaWatch en 2026-09-14T12:00:00.000Z Waters Sets Benchmark for Standardized Spectral Flow Cytometry with Commercial Launch of BD FACSDiscover A7 Cell Analyzer https://www.biopharmawatch.com/news/EVAX/evaxion-ai-immunology-autoimmune-diseases BiopharmaWatch en 2026-09-14T12:00:00.000Z Evaxion applies its AI-Immunology™ platform in autoimmune diseases https://www.biopharmawatch.com/news/AKBA/akebia-first-patient-phase-2-ebribafusp-trial BiopharmaWatch en 2026-09-14T12:00:00.000Z Akebia Therapeutics Announces First Patient Dosed in Phase 2 Basket Trial of Ebribafusp in Rare Complement-Mediated Kidney Diseases https://www.biopharmawatch.com/news/RADX/radiopharm-rad101-phase-2b-trial-data-sno26 BiopharmaWatch en 2026-09-14T12:00:00.000Z Radiopharm Theranostics Selected for Late-Breaking Oral Presentation of Positive Data from Interim Analysis of U.S. Phase 2b Imaging Trial of RAD101 at 2026 Society of Neuro-Oncology Annual Meeting https://www.biopharmawatch.com/news/NSRX/nasus-pharma-fda-clearance-ns002-anaphylaxis-study BiopharmaWatch en 2026-09-14T12:00:00.000Z Nasus Pharma Announces FDA Clearance to Initiate Clinical Study of NS002 in the Treatment of Anaphylaxis https://www.biopharmawatch.com/news/LPCN/lipocine-bloom-phase-3-study-lpcn-1154-postpartum-depression BiopharmaWatch en 2026-09-14T12:00:00.000Z Lipocine Announces Initiation of BLOOM Phase 3 Study of LPCN 1154 for Postpartum Depression https://www.biopharmawatch.com/news/HIND/vyome-appoints-jerry-leonard-cfo BiopharmaWatch en 2026-09-14T12:00:00.000Z Vyome Appoints Experienced Public Company Finance Executive Jerry Leonard as Chief Financial Officer https://www.biopharmawatch.com/news/RHEL/rhelion-filament-fda-hearing-psychedelic-drugs BiopharmaWatch en 2026-09-14T11:53:00.000Z Rhelion Life Sciences' Wholly Owned Subsidiary Filament Health to Deliver Oral Comments at FDA Public Hearing on the Potential Future Therapeutic Use of Psychedelic Drugs https://www.biopharmawatch.com/news/HURA/tuhura-biosciences-fda-clearance-tbs-2025-aml BiopharmaWatch en 2026-09-14T11:45:00.000Z TuHURA Biosciences Receives FDA "Study May Proceed" Notice and IND Clearance for the Evaluation of its TBS-2025 VISTA-Inhibiting Antibody in Molecularly Defined Subsets of AML and Other Blood-Related Cancers https://www.biopharmawatch.com/news/CGC/canopy-growth-shareholder-vote-reminder-september-2023 BiopharmaWatch en 2026-09-14T11:30:00.000Z Canopy Growth Reminds Shareholders to Vote Ahead of September 23 Deadline https://www.biopharmawatch.com/news/OGN/organon-fda-review-miu-della-hormone-free-iud BiopharmaWatch en 2026-09-14T11:30:00.000Z Organon Announces US FDA Has Accepted for Review a Supplemental New Drug Application for MIUDELLA®, a Hormone-Free Intrauterine Device https://www.biopharmawatch.com/news/MDT/medtronic-launches-exchange-offer-minimed-separation BiopharmaWatch en 2026-09-14T11:30:00.000Z Medtronic Launches Exchange Offer to Complete Separation of MiniMed Group, Inc. https://www.biopharmawatch.com/news/MMED/minimed-files-form-s4-registration-statement BiopharmaWatch en 2026-09-14T11:30:00.000Z MiniMed Files Form S-4 Registration Statement in Connection with Medtronic Exchange Offer Announcement https://www.biopharmawatch.com/news/GLAS/glass-house-mama-sue-athlete-balm-launch-california BiopharmaWatch en 2026-09-14T11:30:00.000Z Glass House Brands Releases Mama Sue Professional Athlete Balm for Sale in California https://www.biopharmawatch.com/news/CYTK/cytokinetics-communications-grant-program-2026 BiopharmaWatch en 2026-09-14T11:30:00.000Z Cytokinetics Announces Call for Proposals for Ninth Annual Communications Grant Program https://www.biopharmawatch.com/news/BBNX/beta-bionics-fda-clearance-mint-patch-pump BiopharmaWatch en 2026-09-14T11:30:00.000Z Beta Bionics Announces FDA Clearance of Mint™, the Company’s Transformative Patch Pump, and Unveils 3D Intelligence™ as its Next-Generation Insulin Dosing Algorithm https://www.biopharmawatch.com/news/BCTX/briacell-phase-3-breast-cancer-study-update BiopharmaWatch en 2026-09-14T11:30:00.000Z Data Safety Monitoring Board (DSMB) Recommends Continuing BriaCell’s Phase 3 Metastatic Breast Cancer Study https://www.biopharmawatch.com/news/BKTS/becketts-2026-annual-special-meeting-results BiopharmaWatch en 2026-09-14T11:00:00.000Z Beckett's Announces Results of Its 2026 Annual and Special Meeting of Shareholders and the Granting of Stock Options https://www.biopharmawatch.com/news/BHST/bioharvest-sciences-presentation-hc-wainwright-conference BiopharmaWatch en 2026-09-14T11:00:00.000Z BioHarvest Sciences to Present at the H.C. Wainwright 28th Annual Global Investment Conference https://www.biopharmawatch.com/news/PHIO/phio-fda-submission-phase-2b-carcinoma BiopharmaWatch en 2026-09-14T11:00:00.000Z Phio Announces Key Development Milestone for PH-762 with FDA Submission Supporting Next Stage of Clinical Development in Cutaneous Squamous Cell Carcinoma https://www.biopharmawatch.com/news/BBNX/senseonics-partnership-beta-bionics-eversense-ilet BiopharmaWatch en 2026-09-14T11:00:00.000Z Senseonics Announces Strategic Partnership with Beta Bionics to Integrate Eversense® 365 with the iLet® Bionic Pancreas https://www.biopharmawatch.com/news/CRBP/corbus-pharmaceuticals-announces-positive-topline-data-canyon-1-study-daily BiopharmaWatch en 2026-09-14T11:00:00.000Z Corbus Pharmaceuticals Announces Positive Topline Data from CANYON-1 Study of Daily Oral CRB-913 for the Treatment of Obesity https://www.biopharmawatch.com/news/INMB/inmune-bio-appoints-executives-to-board BiopharmaWatch en 2026-09-14T11:00:00.000Z INmune Bio Appoints Sanofi Rare-Disease Executive and Biopharma Business Development Leader to Board https://www.biopharmawatch.com/news/MDWD/mediwound-escharex-phase-iii-value-study-update BiopharmaWatch en 2026-09-14T11:00:00.000Z Independent DSMB Recommends MediWound’s EscharEx® Phase III VALUE Study Continue Without Modification https://www.biopharmawatch.com/news/LYEL/lyell-immunopharma-baird-2026-healthcare-conference BiopharmaWatch en 2026-09-14T11:00:00.000Z Lyell Immunopharma To Participate in the Baird 2026 Global Healthcare Conference https://www.biopharmawatch.com/news/NRXP/geneuro-awarded-patent-gnk-301-als-treatment BiopharmaWatch en 2026-09-14T11:00:00.000Z GeNeuro, Inc., an NRx Company (Nasdaq:NRXP) is awarded European Patent Rights for GNK-301, a novel drug candidate to treat Amyotrophic Lateral Sclerosis (ALS) https://www.biopharmawatch.com/news/IMCR/immunocore-tebe-am-trial-enrollment-kimmtrak BiopharmaWatch en 2026-09-14T11:00:00.000Z Immunocore announces achievement of target enrollment in registrational TEBE-AM trial with KIMMTRAK® (tebentafusp) in previously treated advanced melanoma https://www.biopharmawatch.com/news/KTTA/pasithea-therapeutics-presentation-pas-004-clinical-data BiopharmaWatch en 2026-09-14T11:00:00.000Z Pasithea Therapeutics Announces Presentation of Initial PAS-004 Clinical Data from Ongoing Phase 1/1b Clinical Trial in Adult NF1 Patients at the 2026 European Neurofibromatosis Conference https://www.biopharmawatch.com/news/SPTX/seaport-therapeutics-september-investor-conferences BiopharmaWatch en 2026-09-14T11:00:00.000Z Seaport Therapeutics to Participate in September Investor Conferences https://www.biopharmawatch.com/news/DFTX/definium-therapeutics-positive-results-phase-3-study BiopharmaWatch en 2026-09-14T11:00:00.000Z Definium Therapeutics Announces Positive Topline Results from Phase 3 Panorama Study of DT120 ODT in Generalized Anxiety Disorder https://www.biopharmawatch.com/news/ARMP/armata-pharmaceuticals-fda-breakthrough-therapy-ap-sa02 BiopharmaWatch en 2026-09-14T11:00:00.000Z Armata Pharmaceuticals Receives U.S. FDA Breakthrough Therapy Designation for AP-SA02 https://www.biopharmawatch.com/news/CGEM/cullinan-therapeutics-virtual-event-rezilient3-data BiopharmaWatch en 2026-09-14T11:00:00.000Z Cullinan Therapeutics to Host Virtual Analyst and Investor Event Today to Feature Zipalertinib Plus Chemotherapy Phase 3 REZILIENT3 Data Presented at the IASLC 2026 World Conference on Lung Cancer https://www.biopharmawatch.com/news/QTTB/q32-bio-appoints-new-executives BiopharmaWatch en 2026-09-14T10:59:00.000Z Q32 Bio Appoints José Trevejo, M.D., Ph.D., as Chief Medical Officer and Ellie Hershberger, Pharm.D., as Chief Development Officer https://www.biopharmawatch.com/news/TYRA/tyra-announces-400-million-offering-common-stock BiopharmaWatch en 2026-09-14T10:45:00.000Z Tyra Announces Pricing of $400 Million Underwritten Offering of Common Stock and Pre-Funded Warrants https://www.biopharmawatch.com/news/TLX/fda-approves-telix-pixclara-brain-cancer-imaging-drug BiopharmaWatch en 2026-09-14T10:30:00.000Z FDA Approves Telix’s Brain Cancer Imaging Drug Pixclara https://www.biopharmawatch.com/news/JNJ/amivantamab-chemotherapy-nsclc-survival BiopharmaWatch en 2026-09-14T08:10:00.000Z Johnson & Johnson’s RYBREVANT®▼ (amivantamab) plus chemotherapy delivers median overall survival of nearly three years in EGFR exon 20 insertion mutation-positive non-small cell lung cancer https://www.biopharmawatch.com/news/ENSC/ensysce-biosciences-fda-hearing-psychedelic-drugs BiopharmaWatch en 2026-09-14T08:00:00.000Z Ensysce Biosciences' Professor Richard Langford Selected to Speak at FDA Public Hearing on the Potential Future Therapeutic Use of Psychedelic Drugs https://www.biopharmawatch.com/news/BNTX/gotistobart-phase-3-study-results-lung-cancer BiopharmaWatch en 2026-09-14T08:00:00.000Z Neue Daten zu Gotistobart zeigten annähernde Verdopplung des medianen Gesamtüberlebens im Vergleich zur Standardchemotherapie bei Patientinnen und Patienten mit zuvor behandeltem Plattenepithelkarzinom der Lunge https://www.biopharmawatch.com/news/BNTX/gotistobart-doubles-survival-squamous-nsclc BiopharmaWatch en 2026-09-14T08:00:00.000Z BioNTech and OncoC4 Present Updated Data Showing Gotistobart Nearly Doubled Median Overall Survival versus Standard-of-Care Chemotherapy in Previously Treated Squamous Non-Small Cell Lung Cancer Patients https://www.biopharmawatch.com/news/NVO/novo-nordisk-rebrand-lasting-health-starts-now BiopharmaWatch en 2026-09-14T07:05:00.000Z Novo Nordisk enters next chapter to bring better health to more people, supported by ‘Novo’ rebrand and updated corporate culture https://www.biopharmawatch.com/news/TAK/fda-accepts-ndas-zasocitinib-plaque-psoriasis BiopharmaWatch en 2026-09-14T07:00:00.000Z U.S. FDA Accepts New Drug Application Under Priority Review for Takeda’s Zasocitinib in Moderate-to-Severe Plaque Psoriasis, with Potential to Redefine Oral Treatment Expectations https://www.biopharmawatch.com/news/CLLS/cellectis-strategic-transformation-in-vivo-gene-editing BiopharmaWatch en 2026-09-14T06:40:00.000Z Cellectis Announces Strategic Transformation To In Vivo Gene Editing Company https://www.biopharmawatch.com/news/NBTX/nanobiotix-phase-1-results-nbtxr3-nsclc BiopharmaWatch en 2026-09-14T06:00:00.000Z NANOBIOTIX Announces Complete Full Cohort Phase 1 Results for JNJ-1900 (NBTXR3) in Inoperable, Recurrent Non-Small Cell Lung Cancer https://www.biopharmawatch.com/news/WHWK/whitehawk-therapeutics-ptk7-adc-target-nsclc-wclc-2026 BiopharmaWatch en 2026-09-14T01:30:00.000Z Whitehawk Therapeutics Presents Real-World Analyses Supporting PTK7 as a Durable ADC Target in EGFR Wild-Type Non-Small Cell Lung Cancer at WCLC 2026 https://www.biopharmawatch.com/news/CGEM/zipalertinib-chemotherapy-nsclc-trial-results BiopharmaWatch en 2026-09-13T23:15:00.000Z Zipalertinib Plus Chemotherapy Demonstrates 6-Month Median Progression-Free Survival Benefit in REZILIENT3 Phase 3 Trial in First-Line EGFR Exon 20 Insertion Mutation Non-Small Cell Lung Cancer https://www.biopharmawatch.com/news/DFTX/definium-therapeutics-panorama-study-results BiopharmaWatch en 2026-09-13T21:00:00.000Z Definium Therapeutics to Discuss Topline Results from Phase 3 Panorama Study in Generalized Anxiety Disorder on September 14, 2026